Abstract | Background: Methods: We performed a retrospective study using a validated electronic medical record (EMR)-based IBD cohort from 2 large tertiary care centers. The index date was the first date of vedolizumab or TNFi prescription. Baseline covariates were assessed 1 year before the index date; patients were followed 1 year after the index date. The primary outcome was arthralgia, defined using NLP. Using inverse probability of treatment weight to balance the cohorts, we then constructed Cox regression models to calculate the hazard ratio (HR) for arthralgia in the vedolizumab and TNFi groups. Results: We studied 367 IBD patients on vedolizumab and 1218 IBD patients on TNFi. Patients on vedolizumab were older (mean age, 41.2 vs 34.9 years) and had more prevalent use of immunomodulators (52.3% vs 31.9%) than TNFi users. Our data did not observe a significantly increased risk of arthralgia in the vedolizumab group compared with TNFi (HR, 1.20; 95% confidence interval, 0.97-1.49). Conclusions: In this large observational study, we did not find a significantly increased risk of arthralgia associated with vedolizumab use compared with TNFi.
|
Authors | Tianrun Cai, Tzu-Chieh Lin, Allison Bond, Jie Huang, Gwendolyn Kane-Wanger, Andrew Cagan, Shawn N Murphy, Ashwin N Ananthakrishnan, Katherine P Liao |
Journal | Inflammatory bowel diseases
(Inflamm Bowel Dis)
Vol. 24
Issue 10
Pg. 2242-2246
(09 15 2018)
ISSN: 1536-4844 [Electronic] England |
PMID | 29846617
(Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Gastrointestinal Agents
- Immunosuppressive Agents
- Tumor Necrosis Factor-alpha
- vedolizumab
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
(adverse effects)
- Arthralgia
(chemically induced, pathology)
- Electronic Health Records
(statistics & numerical data)
- Female
- Follow-Up Studies
- Gastrointestinal Agents
(adverse effects)
- Humans
- Immunosuppressive Agents
(adverse effects)
- Inflammatory Bowel Diseases
(drug therapy, pathology)
- Male
- Natural Language Processing
- Prognosis
- Retrospective Studies
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|